Search

Researchers from Erciyes University conducted a study on non-alcoholic fatty liver disease (NAFLD) and its connection to metabolic disorders. The study focused on the effects of Saccharomyces boulardii (S. boulardii) on fructose-induced NAFLD in rats. Results showed that S. boulardii supplementation reduced lipid accumulation and oxidative stress in the liver, suggesting its potential as a therapeutic intervention for NAFLD. The study highlights the importance of the gut-liver axis and the role of gut microbiota in the pathogenesis of NAFLD. [Extracted from the article]

Researchers at the Affiliated Hospital of Guilin Medical University conducted a study on non-alcoholic fatty liver disease (NAFLD) to understand the role of pyroptosis in the condition. By analyzing gene expression data, they identified key pyroptosis-related genes (PRGs) like TIRAP and GSDMD, which showed high diagnostic efficacy for NAFLD. The study suggests potential therapeutic avenues and enhances the understanding of pyroptosis in NAFLD. The research was published in Scientific Reports and offers insights into the use of machine learning for identifying diagnostic markers in NAFLD. [Extracted from the article]

A study conducted in Mexico City focused on the relationship between non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome risk in pre-pubertal Mexican boys. The research utilized multiparametric MRI (mpMRI) metrics to assess liver fat and disease activity in a cohort of pre-pubertal boys with varying Body-Mass Index (BMI). The findings suggested a potential for using mpMRI for routine pediatric NAFLD screening in high-risk populations. The study was published in Scientific Reports and can be accessed online for further information. [Extracted from the article]

A study conducted at Jahrom University of Medical Sciences in Iran focused on the correlation between ultrasonographic and laboratory-assisted diagnosis of non-alcoholic fatty liver disease (NAFLD) in obese and normal-weight children. The research found that obese and overweight children are 8.5 times more likely to develop NAFLD compared to their normal-BMI peers. The study concluded that liver enzyme panels integrated with ultrasonographic assessment should be utilized for the evaluation of NAFLD in children. [Extracted from the article]

Researchers at Peking Union Medical College conducted a case-control study in China to explore the association between blood calcium, magnesium, and non-alcoholic fatty liver disease (NAFLD) in Chinese adults. The study found a negative association between blood calcium and NAFLD, as well as a U-shaped relationship for blood magnesium and NAFLD. The research suggests that liver function or lipid metabolism parameters may modify the association, indicating the need for individualized prevention strategies for NAFLD. [Extracted from the article]

The patent application titled "Isthmin Protein Therapeutics for the Treatment of Non-Alcoholic Fatty Liver Disease" discusses the potential therapeutic use of ISM1 protein in addressing glucose and lipid-associated disorders, particularly non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The inventors propose that ISM1 protein can dissociate glucose uptake from lipid synthesis, potentially improving diabetes by decreasing insulin resistance and ameliorating hepatic steatosis. The application suggests that ISM1 protein could be administered to individuals to simultaneously treat hyperglycemia and hyperlipidemia, offering a new avenue for addressing metabolic syndrome. [Extracted from the article]

A recent study conducted by Tehran University of Medical Sciences in Iran explored the relationship between fructose and fiber consumption, physical activity, and non-alcoholic fatty liver disease (NAFLD) in children. The study, which included 325 overweight and obese children aged 6-13 years, found that higher intake of legume and nut fiber was significantly associated with a reduced risk of NAFLD. While fructose intake did not show a significant link to NAFLD in this population, further research is needed to confirm these findings and clarify the role of physical activity in NAFLD prevention. [Extracted from the article]

A study conducted at Tanta University in Egypt explored the connection between non-alcoholic fatty liver disease (NAFLD) in pediatric patients and the increased risk of atrial fibrillation (AF) development. The research found that children with NAFLD exhibited prolonged atrial electromechanical properties, which may indicate potential AF in adulthood. This study, supported by Tanta University, highlights the importance of monitoring cardiovascular complications in pediatric patients with NAFLD. [Extracted from the article]

The article discusses the susceptibility of individuals with non-alcoholic fatty liver disease (NAFLD) to systemic inflammation, such as sepsis, which can accelerate liver damage. The study found that short-term Choline Deficient High Fat Diet (HFCD)-fed mice were more susceptible to mortality after a lipopolysaccharide (LPS) challenge due to the excessive accumulation of specific neutrophils in the liver tissue. Inhibiting IFN{gamma} or blocking PD-L1 effectively modulated the recruitment of these neutrophils, reducing hepatic damage and mortality risk. The research aims to develop strategies to control hyperinflammatory responses in patients with HFCDs to prevent liver damage and mortality. [Extracted from the article]

Researchers at Longyan First Affiliated Hospital of Fujian Medical University conducted a study on the relationship between blood manganese levels and non-alcoholic fatty liver disease (NAFLD) in children, with a focus on cotinine exposure. The study found that blood manganese is an independent risk factor for pediatric NAFLD, and cotinine exposure can enhance this relationship. The researchers suggest that reducing cotinine exposure may help mitigate the negative effects of heavy metal exposure in children. [Extracted from the article]

Researchers from the University Finis Terrae in Santiago, Chile, conducted a study on the prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in adults in Chile and its association with lifestyle habits. The study found that approximately one out of four adults in Chile has NAFLD, with prevalence increasing with higher body mass index (BMI). Lifestyle habits such as less smoking, more physical activity, and whole-grain consumption were associated with lower odds of having NAFLD. The researchers concluded that health promotion strategies focusing on controlling excess body weight and promoting specific lifestyle habits are urgently needed. [Extracted from the article]

A study conducted by researchers from Jilin University in Changchun, People's Republic of China, explored the relationship between serum vitamin D levels and non-alcoholic fatty liver disease (NAFLD). The study, based on data from the 2017-2018 National Health and Nutrition Examination Survey, found that adequate serum vitamin D was a protective factor for NAFLD, with body mass index (BMI) mediating a portion of this association. The research concluded that BMI partly mediated the link between serum vitamin D and NAFLD. [Extracted from the article]

A multi-center, prospective, cohort study aims to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes and evaluate the clinical usefulness of Dapagliflozin/Pioglitazone combination therapy. The study, NCT06649162, is recruiting 10,000 participants in Korea, Republic of, with a primary completion date of March 31, 2027. The research focuses on patients with type 2 diabetes who are scheduled to receive the combination therapy and aims to assess their risk of developing NAFLD. [Extracted from the article]

A recent study conducted at the Affiliated People's Hospital of Ningbo University explored the relationship between high levels of serum hypersensitive C-reactive protein (hs-CRP) and non-alcoholic fatty liver disease (NAFLD) in non-obese individuals. The research found that the prevalence of NAFLD increases with higher levels of hs-CRP in both men and women. Hs-CRP was identified as an independent risk factor for NAFLD, even after adjusting for relevant variables. This study provides valuable insights for risk prediction and clinical screening in high-risk populations. [Extracted from the article]

Researchers from Second Hospital of Dalian Medical University have conducted a study on non-alcoholic fatty liver disease (NAFLD), a condition characterized by fat accumulation without excessive alcohol consumption. The research highlights the role of heat shock proteins (HSPs) in NAFLD pathogenesis, emphasizing their potential therapeutic applications. By understanding the molecular mechanisms of HSP-mediated protection in NAFLD, targeted therapies for this prevalent liver disorder may be developed. [Extracted from the article]

The University of Austral in Buenos Aires, Argentina, conducted research on the role of Secreted Protein Acidic and Rich In Cysteine (SPARC) in obesity, type 2 diabetes, and non-alcoholic fatty liver disease. The study found that SPARC plays a significant role in adipogenesis, cellular metabolism, extracellular matrix modulation, and glucose and lipid metabolism. This research suggests that SPARC could be a potential target for therapeutic interventions or a biomarker for disease progression in these conditions. The findings were published in the Journal of Physiology and Biochemistry and have been peer-reviewed. [Extracted from the article]

Researchers at Suzhou Ninth People's Hospital conducted a study on lipid metabolism disorders, focusing on the impact of Hepatocyte nuclear factor 1 homeobox A (HNF1A) on type 2 diabetes combined with non-alcoholic fatty liver disease (NAFLD). The study found that knockdown of HNF1A improved glucose and lipid metabolism disorders in mice with high-fat diet and hyperglycemia, as well as modulated the PI3K/AKT/mTOR signaling pathway. The research suggests that targeting HNF1A could be beneficial in ameliorating type 2 diabetes and NAFLD. For more information, the study is published in the Journal of Men's Health. [Extracted from the article]

A study conducted in Mexico City examined the incidence of non-alcoholic fatty liver disease (NAFLD) in people living with HIV who were starting antiretroviral therapy. The research found that there was a high incidence of NAFLD in this population, with risk factors including baseline overweight, low HDL-cholesterol, and specific biomarkers at 48 weeks of treatment. The study concluded that these findings highlight the importance of monitoring and managing liver health in individuals with HIV starting antiretroviral therapy. [Extracted from the article]

Researchers at Shanxi University in China have conducted a study on non-alcoholic fatty liver disease (NAFLD), a serious health threat with no effective treatment. Their research focused on the potential benefits of isorhamnetin found in quinoa whole-grain flavonoids in mitigating NAFLD by modulating bile acid metabolism through the regulation of specific genes. The study suggests that isorhamnetin shows promise as a treatment for NAFLD due to its lipid-lowering and hepatoprotective activities. For more information, the full article can be accessed through the publisher MDPI AG. [Extracted from the article]

A recent study conducted at Wannan Medical College in Wuhu, People's Republic of China, focused on developing a polarity-sensitive fluorescent probe using coumarin derivatives to image lipid droplets and diagnose non-alcoholic fatty liver disease (NAFLD). The research aimed to monitor changes in lipid droplets' polarity in real-time to accurately diagnose associated diseases. The study successfully designed and synthesized four novel fluorescent probes, with XOT3 showing promising results in visualizing intracellular lipid droplets and monitoring alterations in their polarity during various conditions. This research provides a powerful tool for the early diagnosis of NAFLD and has been peer-reviewed. [Extracted from the article]

A recent report from researchers at the National and Kapodistrian University of Athens explores the bidirectional association between non-alcoholic fatty liver disease (NAFLD) and coronary artery disease (CAD) based on endothelial dysfunction (EnD). NAFLD is linked to insulin resistance, obesity, and diabetes mellitus, increasing the risk of cardiovascular complications. The study aims to examine the pathophysiological mechanisms and genetic background underlying this relationship, discussing potential clinical implications and treatment options for patients with NAFLD and CAD. For more information, the full article is available in the International Journal of Molecular Sciences. [Extracted from the article]

A recent study conducted at Capital Medical University in Beijing, China, explored the effects of an 11 beta-hydroxysteroid dehydrogenase type 1 inhibitor on non-alcoholic fatty liver disease in mice. The research found that the inhibitor improved glucolipid metabolism, insulin resistance, and reduced the severity of non-alcoholic fatty liver disease in mice. The study concluded that the inhibitor's mechanism likely involves decreased liver corticosterone levels and enhanced hepatocyte autophagy through specific signaling pathways. [Extracted from the article]

A study conducted at the Beijing Institute of Technology in Zhuhai, China, focused on the role of immune cells in the pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD). The research highlighted the complex interplay of immune cells in NAFLD development and potential therapeutic implications. The study aims to contribute to the future development of NAFLD therapeutics. [Extracted from the article]

A study conducted at Guangdong Pharmaceutical University investigated the effects of Camellia petelotii Chi extract on non-alcoholic fatty liver disease (NAFLD) in rats. The research found that the extract improved liver damage by regulating glucose and lipid metabolism, reducing inflammation, and improving liver function through the TLR-4/NF-kB signaling pathway. The study concluded that the high dose of Camellia petelotii Chi extract had the most significant positive impact on NAFLD rats. [Extracted from the article]

A recent study conducted in Vila do Conde, Portugal, explored the relationship between sarcopenia (muscle loss) and non-alcoholic fatty liver disease (NAFLD). The systematic review found that low muscle mass and strength were associated with the presence and severity of NAFLD. However, standardization of assessment methods is needed in this area, and specific guidance on sarcopenia in NAFLD could be beneficial. The study was published in Sci and can be accessed for free online. [Extracted from the article]

A new report discusses the global health issue of non-alcoholic fatty liver disease (NAFLD), which is closely linked to metabolic dysfunctions such as obesity and type 2 diabetes. The report focuses on the gut-liver axis, a communication pathway between the liver and the gut, and explores the influence of gut microbiota, intestinal permeability, and inflammatory pathways in the development of NAFLD. The report also discusses potential therapeutic strategies, including fecal microbiota transplantation, phage therapy, and the use of specific probiotics, prebiotics, and postbiotics. Understanding these interactions can help identify potential therapeutic targets for NAFLD. [Extracted from the article]

A study conducted by Sun Yat-sen University in Guangdong, China, examined the association between ultra-processed food (UPF) consumption and severe non-alcoholic fatty liver disease (NAFLD). The study included 143,073 participants from the UK Biobank and found that higher UPF intake was linked to an increased risk of severe NAFLD. The risk was particularly elevated in individuals with a BMI of 25 or higher. The researchers concluded that reducing UPF intake could be a potential strategy to lower the risk of NAFLD. This research has been peer-reviewed and published in The Journal of Nutrition Health & Aging. [Extracted from the article]

A recent study conducted by researchers at Xinjiang University in China explores the relationship between probiotics and non-alcoholic fatty liver disease (NAFLD). The study highlights the significant roles played by Lactobacillus plantarum and Bifidobacterium bifidum in manipulating lipid synthesis genes and proteins to reduce hepatic lipid accumulation and oxidative stress, key components of NAFLD progression. These probiotics also modulate gut microbiota, combat harmful bacteria, alleviate inflammation, and bolster the intestinal mucosal barrier. The findings propose probiotics as a promising natural method to slow down NAFLD progression and improve microbiome-focused treatments for the disease. [Extracted from the article]

A recent study conducted by researchers at Shiraz University of Medical Sciences in Iran explored the relationship between dietary insulin index (DII) and dietary insulin load (DIL) and the risk of non-alcoholic fatty liver disease (NAFLD). The study found that adherence to a diet with a high DII and DIL was associated with an increased risk of NAFLD. These findings may be valuable for healthcare providers in developing preventive measures for individuals at risk of NAFLD. The study was a cross-sectional study involving 3,158 participants in Tehran, Iran. [Extracted from the article]

Researchers at hy Co. Ltd. in South Korea have conducted a study on the effects of a probiotic lactic acid-generating bacteria (LAB) on non-alcoholic fatty liver disease (NAFLD) in mice. The LAB, known as Lactocaseibacillus paracasei HY7207 (HY7207), was found to reduce fat accumulation and improve liver health in mice with NAFLD. The study showed that HY7207 reduced the expression of genes related to lipogenesis, inflammation, and fibrosis in the liver. These findings suggest that HY7207 may be a suitable functional food supplement for patients with NAFLD. [Extracted from the article]

A recent study conducted by the Karolinska Institute in Stockholm, Sweden, explored the association between changes in dietary fat intake and plasma fatty acid composition in patients with non-alcoholic fatty liver disease. The study found that modifying the composition of dietary fats during weight loss treatment can lead to changes in the plasma fatty acid profile, which are associated with changes in liver fat, stiffness, plasma cholesterol, and triglycerides. The researchers concluded that replacing saturated fatty acids with polyunsaturated fatty acids may improve metabolic parameters in patients with non-alcoholic fatty liver disease. This research has been peer-reviewed and provides valuable insights into the management of this condition. [Extracted from the article]

A recent study conducted by researchers at Harbin Medical University explores the role of peroxisome proliferator-activated receptor gamma (PPARg) in non-alcoholic fatty liver disease (NAFLD). NAFLD is a chronic condition characterized by liver dysfunction and the accumulation of fat and extracellular matrix. The study aims to investigate the molecular mechanisms underlying NAFLD and the potential therapeutic effects of PPARg. The research findings provide new insights into the pathogenesis of NAFLD and may contribute to the development of specific therapeutic strategies. [Extracted from the article]

A study conducted by the Department of Rehabilitation in Japan examined the relationship between relative fat mass (RFM) and the risk of non-alcoholic fatty liver disease (NAFLD) in the Japanese population. The study included 14,250 Japanese adults and found a significant positive correlation between RFM and NAFLD risk. The study also identified a non-linear relationship between RFM and NAFLD incidence, with a threshold identified for both men and women. The findings suggest that maintaining a lower RFM may help mitigate the risk of NAFLD. [Extracted from the article]

A study conducted by researchers at Western University of Health Sciences examined the effect of statin use on liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease (NAFLD). The study analyzed data from the US NHANES database from 2009 to 2018 and included 2,533 adults with NAFLD. The results showed that statin use was not associated with elevated liver enzymes in patients with NAFLD. Additionally, statin users had significantly lower levels of ALT, total cholesterol, and LDL compared to non-statin users. This research provides real-world evidence of the safety and effectiveness of statin use in patients with NAFLD. [Extracted from the article]

A recent study conducted by the Department of Pharmacy aimed to investigate the metabolic changes occurring in alcoholic fatty liver disease (AFLD) and develop a diagnostic method based on blood metabolomics. The study used a rat model of AFLD and analyzed metabolic data using a support vector machine (SVM) model. The SVM model achieved a classification accuracy of 100% and identified statistically significant differences in metabolic, hepatic function, and pharmacokinetic changes between the AFLD group and the control group. The study concluded that metabolic ability is heightened in the early stage of AFLD, and the SVM model can be used to detect early changes in AFLD based on metabolic data. [Extracted from the article]

A recent report from the Russian Academy of Sciences discusses the role of non-coding RNAs in the regulation of signaling pathways in non-alcoholic fatty liver disease (NAFLD). The researchers highlight the contribution of peroxisome proliferator-activated receptors (PPARs) to changes in lipid metabolism and the development of lipotoxicity in NAFLD. They also identify microRNAs and long non-coding RNAs (lncRNAs) that may be associated with the regulation of these signaling pathways and could potentially serve as markers for differentiating clinical forms and severity of NAFLD. The research emphasizes the importance of understanding these molecular mechanisms in order to develop effective diagnostic and therapeutic strategies for NAFLD. [Extracted from the article]

Researchers at Guangxi University in the People's Republic of China have developed a novel fluorescent probe called TEM-NS that can accurately measure peroxynitrite (ONOO-) levels in non-alcoholic fatty liver disease (NAFLD). ONOO- is a biomarker associated with pathological changes in biological tissue and is linked to the development of NAFLD. The probe demonstrated high specificity, sensitivity, and photostability, making it a valuable tool for studying oxidative stress-related disorders. The research was supported by the National Natural Science Foundation of China and the National Natural Science Foundation of Guangxi Province. [Extracted from the article]

A study conducted by researchers at Henan University of Technology in Zhengzhou, China, explored the effects of Lacticaseibacillus rhamnosus LRa05 on alcoholic fatty liver disease (ALD) in mice. The study found that LRa05 intervention significantly reduced liver injury caused by alcohol consumption by decreasing triglyceride levels and suppressing inflammatory responses. LRa05 also improved intestinal permeability and balanced the gut microbiota, potentially contributing to its protective effects against ALD. The study suggests that LRa05 may have reconstructive effects on the gut microbiota, which could be linked to its efficacy in improving gut permeability and protecting against ALD. [Extracted from the article]

A recent study conducted by researchers at Wannan Medical College in Wuhu, China, has focused on understanding the role of lipid droplets (LDs) in diseases such as non-alcoholic fatty liver disease (NAFLD). The researchers synthesized four fluorescent probes to monitor the polarity of LDs and found that two of the probes, CNL2 and CNL4, exhibited high sensitivity and specificity for polarity changes. These probes were able to effectively monitor changes in LDs polarity under conditions of ferroptosis and oxidative stress, showing potential for diagnosing NAFLD tissue and studying lipophagy. The findings of this study contribute to a deeper understanding of NAFLD progression and provide new tools for diagnosing and treating related diseases. [Extracted from the article]

A recent meta-analysis conducted by researchers at Iran University of Medical Sciences found that synbiotics supplementation can have positive effects on patients with non-alcoholic fatty liver disease (NAFLD). The study analyzed randomized controlled trials and found that synbiotics supplementation significantly improved liver enzymes, lipid profile, obesity indices, blood pressure, and inflammatory markers in patients with NAFLD. The researchers concluded that overall, synbiotics supplementation can be beneficial for patients with NAFLD. This research provides new insights into the potential treatment of NAFLD using synbiotics. [Extracted from the article]

Researchers at Lincoln Medical Center have published a new report on non-alcoholic fatty liver disease (NAFLD) and its connection to sarcopenia, a skeletal muscle disorder. Both conditions share common risk factors and underlying mechanisms, such as insulin resistance and chronic inflammation. The report explores the pathophysiological links between NAFLD and sarcopenia and discusses non-pharmacologic and emerging pharmacologic management strategies for patients with sarcopenia-associated NAFLD. These strategies include weight reduction, diet, alcohol and smoking cessation, physical activity, and the use of supplements and testosterone therapy. The research aims to improve care and intervention for patients with these conditions. [Extracted from the article]

A recent study conducted by researchers at NOVA Southeastern University explores the role of nuclear receptor superfamily members in non-alcoholic fatty liver disease (NAFLD) and potential approaches to treatment. NAFLD is characterized by the accumulation of fat in hepatocytes and can progress to non-alcoholic steatohepatitis (NASH), which is associated with inflammation. The study suggests that agents targeting nuclear receptors, such as thiazolidinediones (TZDs), may be potential treatments for NAFLD and NASH. However, further research is needed to develop tissue-specific ligands that do not interfere with other nuclear receptors. Currently, lifestyle changes, such as weight reduction and reduced fat intake, are the main treatment options for NAFLD. [Extracted from the article]

A recent study conducted by Babol University of Medical Sciences examined the thyroid function tests in overweight and obese children and adolescents with and without non-alcoholic fatty liver disease (NAFLD). The study found that there was no significant difference in the mean level of thyroid hormones between the two groups, and hypothyroidism was not observed. However, there were differences in the levels of AST, ALT, TG, HDL, and BMI between the two groups. The researchers suggest that further studies with larger sample sizes and longer durations are needed to explore this topic further. [Extracted from the article]

A study conducted by researchers from Shanxi Agricultural University in China explores the cross-generational effects of dietary sea buckthorn on non-alcoholic fatty liver disease (NAFLD) in the offspring of obese female mice. The study found that feeding sea buckthorn to maternal mice improved liver steatosis and lipid deposition in their offspring, reduced inflammation-related factors, inhibited the IkB/NF-kB pathway, and decreased the occurrence of NAFLD. The research suggests that sea buckthorn could be a novel strategy for treating NAFLD at the maternal level. [Extracted from the article]

A recent study conducted by researchers at Shandong First Medical University and Shandong Academy of Medical Sciences in China has explored the potential of a flavanone called Kurarinol (KUR) in treating non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC). The study found that KUR effectively reduced lipid deposition and inflammation in hepatocytes, inhibited the proliferation of HCC cell lines, and suppressed NAFLD-HCC formation in mice. These effects were attributed to the suppression of epidermal growth factor receptor (EGFR) signaling. The findings suggest that KUR may be a promising strategy for preventing NAFLD-HCC through EGFR signaling suppression. [Extracted from the article]

A recent meta-analysis conducted by Mayo Clinic researchers evaluated the effectiveness of mobile health intervention (mHI) for non-alcoholic fatty liver disease (NAFLD). The study found that mHI, which involves the use of mobile health technologies, significantly reduced weight and liver markers in patients with NAFLD. The findings suggest that mHI could play a crucial role in managing NAFLD and improving patient outcomes. NAFLD is the most common cause of chronic liver disease worldwide, and lifestyle modification is currently the main approach to management. [Extracted from the article]

A recent study conducted at the Chinese University of Hong Kong has explored the potential benefits of using the prebiotic inulin to prevent and treat non-alcoholic fatty liver disease (NAFLD). The study found that inulin has hepatoprotective effects, including anti-liver injury, anti-inflammatory, and antioxidant activities. While most of the research has been conducted on animals, the study suggests that further research is needed to determine the safe and effective dosage for human use. Inulin is readily available as a supplement and is often combined with probiotic bacteria in synbiotic supplements. [Extracted from the article]

A recent study conducted at Zhejiang Hospital in China explored the effects of ginsenoside R3 (Rg3) on non-alcoholic fatty liver disease (NAFLD) and the underlying mechanism. The study used a high-fat diet to establish an NAFLD mouse model and found that Rg3 alleviated liver function decreases, reversed pathological injury, and reduced hepatic lipid accumulation and inflammatory lesions. The study also demonstrated that Rg3 inhibited lipid accumulation, apoptosis, and inflammatory factors in primary mouse hepatocytes. However, further clinical trials are needed to validate the therapeutic potential of Rg3 for NAFLD treatment. [Extracted from the article]

Non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated steatotic liver disease (MASLD), is the most common chronic liver disease worldwide. There are currently no approved drugs for MASLD, but research is being conducted on various therapeutic strategies. These include antidiabetic agents, targeting hepatic lipid accumulation, addressing oxidative stress, inflammation, and fibrosis, modulating the gut-liver axis, and exploring combination therapies. The expanding pipeline of drug candidates offers hope for effective treatments, and combination therapies may play a crucial role in managing this complex disease. [Extracted from the article]